DTEBOP2: Bayesian Optimal Phase II Randomized Clinical Trial Design with
Delayed Outcomes
Implements a Bayesian Optimal Phase II design (DTE-BOP2) for trials with delayed treatment effects, particularly relevant to immunotherapy studies where treatment benefits may emerge after a delay. The method builds upon the BOP2 framework and incorporates uncertainty in the delay timepoint through a truncated gamma prior, informed by expert knowledge or default settings. Supports two-arm trial designs with functionality for sample size determination, interim and final analyses, and comprehensive simulation under various delay and design scenarios. Ensures rigorous type I and II error control while improving trial efficiency and power when the delay effect is present. A manuscript describing the methodology is under development and will be formally referenced upon publication.
Version: |
1.0.3 |
Depends: |
R (≥ 3.5.0) |
Imports: |
truncdist, doParallel, foreach, parallel, invgamma |
Suggests: |
knitr, rmarkdown, survRM2adapt, ggplot2, reconstructKM, survival, survminer |
Published: |
2025-05-09 |
Author: |
Zhongheng Cai [aut, cre],
Haitao Pan [aut] |
Maintainer: |
Zhongheng Cai <zhonghengcai123 at gmail.com> |
License: |
GPL-3 |
NeedsCompilation: |
no |
CRAN checks: |
DTEBOP2 results |
Documentation:
Downloads:
Linking:
Please use the canonical form
https://CRAN.R-project.org/package=DTEBOP2
to link to this page.